Archivo de informes
Todos los análisis
Página 12 de 52 · 1235 informes
42/100
JCET: Advanced-Packaging Ambitions Are Real, But Owner Earnings Haven't Caught Up to the Price
JCET (Jiangsu Changjiang Electronics Technology) is mainland China's largest chip-assembly, advanced-packaging and test provider (OSAT), running production bases in China, Singapore and South Korea for global computing, automotive, storage and industrial customers. The core tension: 2025 revenue rose 8.1% to CNY 38.87 billion but net profit fell 2.8% to CNY 1.57 billion and operating cash flow dropped 20.3%, while the stock still traded near 101x trailing earnings and 5.5x book after a violent stretch in which a CNY 7.8 billion Lingang advanced-packaging plant announcement was followed by a 9.97% one-day drop on a strong H1 2026 profit pre-announcement. Rating Watch: a genuine advanced-packaging franchise with visibly improving mix, but a share price that has run further than owner earnings and capex-adjusted cash flow currently support.
38/100
57Buffett
Zijin Mining: A Real Multi-Metal Compounder, Priced for the Transition to Go Right
Zijin Mining is a dual-listed (Shanghai + Hong Kong) Chinese mining major that has grown from a domestic gold champion into a global gold-copper-lithium portfolio spanning 18 countries, with a roughly 5.5 billion CAD acquisition of Allied Gold's African assets still unclosed as of 2026-07-22. In 2025 revenue rose to CNY 349.1 billion and operating cash flow to CNY 75.4 billion, and first-quarter 2026 net profit jumped 98% to CNY 20.1 billion as mining-enterprise gross margin reached 71.01% and lithium carbonate output surged more than tenfold to 16.2 thousand tonnes. Rating Hold: cash generation and portfolio breadth are genuinely strong, but at CNY 30.21 the A-share already sits inside the fair-value range, leaving limited margin of safety until Allied closes and Kamoa's copper output normalizes.
45/100
64Buffett
Luxshare Precision: A Good Company, but Only a Fair Price
Luxshare Precision is a Shenzhen-listed, Apple-anchored precision manufacturer that has climbed from connectors into a full-stack platform spanning consumer electronics, communications and data-center hardware, and, since absorbing Germany's Leoni, global automotive wiring. In 2025 the newer engines outgrew the legacy base: automotive electronics revenue surged 185.34% to CNY 39.26 billion and communications and data-center revenue rose 33.81% to CNY 24.57 billion at 18.40% gross margin, even as CNY 17.90 billion of capex consumed nearly all of the year's CNY 17.33 billion operating cash flow and one unnamed customer still supplied 56.68% of sales. Rating Hold: a genuinely higher-quality transition story, but one already priced around 24x forward earnings and roughly 44x owner earnings, leaving little margin of safety for a fresh buyer.
45/100
Daiichi Sankyo: A World-Class ADC Franchise, Priced as If the Supply Crisis Is Already Resolved
Daiichi Sankyo is a Japan-based, oncology-focused pharmaceutical company whose profit engine has shifted to the DXd antibody-drug-conjugate platform, led by Enhertu (partnered with AstraZeneca) and Datroway, with the Oncology unit generating JPY 608.8 billion of FY2025 revenue, up 31.3% year on year. In May 2026 the company booked JPY 214.4 billion of manufacturing-related provisions after admitting its ADC supply contracts were sized for maximum-demand scenarios, yet still posted record FY2025 revenue of JPY 2,123.0 billion and guided FY2026 core operating profit up 27.5%, even as it acknowledged that some medium- to long-term supply-cost gaps remain unrecognized. Rating Hold: world-class ADC science, but a stock that has already re-priced into the acceptable-hold zone rather than a clear bargain, with the next proof point resting on two to three clean quarters without another supply-related charge.
48/100
SpaceX: A Strategically Brilliant Platform Wrapped in a Still-Expensive Stock
SpaceX is a newly public, vertically integrated space and AI conglomerate built on three very different businesses: a mature $11.4 billion Starlink broadband franchise that funds the group, a still-loss-making Space/Starship launch arm, and an AI segment (merged with xAI in February 2026) that lost $6.36 billion in 2025 alone. Since its record $75 billion IPO priced the company near $1.77 trillion, the stock has fallen roughly 45% to $124.11, yet still trades near 87x sales while Elon Musk retains 85.1% of voting power under an unusually investor-unfriendly governance structure. Rating Avoid: a genuinely rare platform, but a public price that still assumes flawless execution across Starship, AI, and an August lock-up event with no real margin of safety.
40/100
Nidec Corporation: A Real Motor Franchise Wrapped in a Credibility Discount
Nidec is Kyoto's diversified motor giant, spanning small precision motors, automotive motion systems, and industrial motors across 300-plus group companies built through 75-plus acquisitions. A founder-rooted accounting scandal has triggered a TSE special-alert designation, a suspended dividend, and a pending review of roughly JPY 250 billion in goodwill, even as FY2025 operating profit held at JPY 237.8 billion on JPY 2.608 trillion in sales. Rating Watch: a real industrial franchise wrapped in a credibility discount, not yet cheap enough or de-risked enough to buy.
36/100
BioNTech SE: Cash-Rich Transition, Unproven Oncology Payoff
BioNTech is a German biotech converting one extraordinary COVID-vaccine windfall into a late-stage oncology franchise, backed by €16.8 billion of cash as of Q1 2026. Revenue is collapsing toward a seasonal COVID trough while R&D spending stays heavy, and pumitamig plus gotistobart carry most of the market's oncology hopes. Rating Hold: the balance sheet rules out a bearish call, but unresolved oncology execution and founder-succession risk keep the price fair rather than cheap.
52/100
95Buffett
Mindray Bio-Medical: The Transition Is Real, But So Is the Price Tag
Shenzhen Mindray is China's largest medical-device platform, spanning patient monitoring, in-vitro diagnostics and imaging, with overseas sales above 53% of revenue and recurring business nearing 40% as the APT Medical deal pushes into consumables and intervention. FY2025 revenue fell 9.4% to RMB 33.28 billion and attributable profit dropped to RMB 8.14 billion as domestic hospital budgets tightened, even as international growth stayed healthy and operating cash flow held at RMB 10.14 billion. Rating Hold: a genuine quality compounder mid-transition, but at CNY 150.31 the price already sits inside the acceptable-hold band, leaving little margin of safety until domestic demand stabilizes.
42/100
TDK Corporation: A Real Transition, Priced With Little Room to Wobble
TDK Corporation is a Japanese materials-and-components maker whose four segments -- Passive Components, Sensors, Magnetic Applications, and Energy (batteries, largely the consolidated ATL battery business) -- sell into AI data centers, automotive, and consumer electronics. FY2026 revenue reached a record ¥2.50 trillion with operating profit of ¥272.4 billion on strong nearline-HDD and sensor demand, but Energy still generated more than half of group revenue and the large majority of segment profit, and management guides Energy down for FY2027. Rating Hold: the AI-diversification story is real, but the price already assumes it succeeds, leaving little margin of safety if execution slips.
46/100
57Buffett
SS&C Technologies: A Sticky Cash Engine, Not Yet Cheap Enough
SS&C Technologies is a financial-software-and-outsourced-operations platform embedded in the back-office workflows of asset managers, fund administrators, and healthcare payers, built through roughly 70 acquisitions since 1986 rather than organic product development alone. FY2025 revenue reached $6.27 billion with $1.74 billion of operating cash flow, and organic growth improved to 5.0% in Q1 2026, but goodwill and intangibles still make up about 68% of total assets, AI investments remain economically undisclosed, and one-segment reporting leaves investors dependent on voluntary disclosure. Rating Hold: a genuinely sticky, cash-generative platform whose current price near the conservative-scenario fair value already reflects most of its quality, leaving only a modest margin of safety.
44/100
AbCellera Biologics: A Well-Funded Platform Waiting on One Clinical Proof Point
AbCellera Biologics is a clinical-stage antibody company transitioning from a partner-fee-and-royalty platform to owning its own drug pipeline, anchored by lead candidate ABCL635 heading into Phase 2 data. FY2025 revenue reached $75.1 million but the company still lost $146.4 million, leaving about $655 million of liquidity to fund the transition. Rating Watch: a well-capitalized platform that still needs ABCL635's Q3 2026 efficacy readout before the transition story can be trusted.
42/100
Silex Systems: A Scarce Enrichment Option Priced for Commercial Success It Has Yet to Earn
Silex Systems is not a uranium miner but a technology-commercialisation vehicle whose value rests on the SILEX laser enrichment process and a 51% stake in Global Laser Enrichment, the scarce listed proxy for rebuilding Western uranium-enrichment capacity. October 2025's independently validated TRL-6 milestone and U.S. policy support are real, yet the parent still burns negative owner earnings after roughly A$36m of annual GLE funding, and at A$4.50 the shares already trade above the A$3.70 conservative fair value. Rating Hold: genuine technical and policy progress, but the stock prices in a large amount of licensing and commercialisation success before it is earned.
47/100
56Buffett
Ningbo Orient Wires & Cables: A Real Submarine-Cable Moat Priced for Flawless Backlog Conversion
Ningbo Orient Wires & Cables is China's specialist in submarine and high-voltage transmission cable systems, having grown 2025 revenue to CNY 10.84 billion behind a CNY 18.41 billion project backlog running 1.7 times that base. Submarine and high-voltage cable revenue jumped 65.6% in 2025 to near half of sales, yet receivables and inventory are swelling just as fast and the current CNY 38.93 price already sits above the conservative buy zone. Rating Watch: a genuine niche moat already priced for flawless backlog conversion, leaving little room for timing mistakes.
42/100
49Buffett
QIAGEN: Sticky Workflow Economics With Takeover Optionality Already in the Price
QIAGEN is a molecular diagnostics and life-science tools company that monetizes an entire lab workflow, from sample prep to assays, automation and bioinformatics, selling to more than 500,000 customers across five growth pillars that target about $1.61 billion of 2026 sales. The recurring consumables model is genuinely sticky, but core organic growth still needs repair while the stock carries takeover optionality after Reuters reported KKR and strategic interest. Rating Hold: at $41.51 the shares sit inside the acceptable-hold band of $39-53, above the ideal buy zone of $30-32, so buyers are paying for both a standalone repair and a deal premium that may not arrive.
40/100
Paladin Energy: The Restart Is Working, and the Price Already Knows It
Paladin Energy is an Australian-listed uranium miner whose cash engine is the 75%-owned Langer Heinrich restart in Namibia, with Patterson Lake South in Saskatchewan as a later-dated growth option targeting first production in 2031. March-2026 quarterly production reached 1.29 million pounds with plant recovery at 92%, prompting management to raise FY2026 guidance to 4.5-4.8 million pounds, yet the December-2025 half-year still showed a US$15.1 million statutory after-tax loss and PLS carries a US$1.226 billion pre-production capital estimate. Rating Hold: at A$9.18 the stock sits inside the acceptable-hold band of A$8.0-10.8, above the ideal buy zone of A$6.0-7.0, paying roughly fair value for a successful ramp plus meaningful PLS credit.
36/100
Trina Solar: Surviving the Solar Glut While the Old Profit Engine Is Still Underwater
Trina Solar is a Chinese solar manufacturer spanning modules, storage, system solutions, and digital energy, with 2025 module shipments of 67.879 GW keeping it in the industry's second tier. 2025 revenue fell 16.61% to RMB 66.98 billion with a RMB 7.03 billion net loss and a negative PV-product gross margin, while storage revenue grew 83.3% at a 14.69% gross margin, real new businesses that are still too small to carry the group. Rating Hold: at CNY 12.18 the stock sits inside the acceptable-hold band of CNY 10.8-14.4, above the ideal buy zone of CNY 9.0-9.8.
47/100
64Buffett
Exelixis: A Real Cabozantinib Cash Machine Pricing In an Unproven Second Act
Exelixis is a commercial-stage oncology biotech whose economics still flow almost entirely through cabozantinib, sold as CABOMETYX in the U.S. and monetized abroad through royalty deals with Ipsen and Takeda. 2025 total revenue reached $2.320 billion with $782.6 million of net income and $884.3 million of operating cash flow, and the market now waits on a December 3, 2026 FDA decision for zanzalintinib in colorectal cancer, the company's attempt to build a second franchise. Rating Hold: the cabozantinib business is real and cash-generative, but at $55.75 the price already assumes a credible handoff to zanzalintinib, leaving limited margin of safety either way.
41/100
Energy Fuels: A Genuine Uranium Ramp, Priced Ahead of an Unbuilt Rare-Earth Chain
Energy Fuels operates White Mesa, the only fully licensed conventional uranium mill in the U.S., and is using that platform to move from uranium ore processing into rare-earth separation and critical-minerals feedstock through the Base, ASM, and VAC deals. 2025 revenue was just $65.9 million with an $85.6 million net loss, yet the stock trades at a $3.17 billion market cap that already prices in a mine-to-magnet chain still years from closing and commercializing. Rating Hold: the uranium ramp is real and improving, but at $12.67 the shares already bank future rare-earth and magnet success, leaving little margin of safety.
44/100
Hangzhou Tigermed: A Genuine China CRO Recovery, Priced Ahead of Clean Earnings
Hangzhou Tigermed is China's largest homegrown clinical CRO, running a domestic clinical-trial franchise alongside a fast-growing overseas and laboratory-services business that together produced RMB 6.83 billion of 2025 revenue. Bookings and backlog both re-accelerated in 2025 (net new bookings up 20.6%, backlog up 15.4%) and first-quarter 2026 operating cash flow rose 60.5%, yet adjusted attributable profit still fell 58.5% to RMB 355 million and the controlling shareholders have been under CSRC investigation over historical disclosure issues since May 2026. Rating Hold: the recovery in orders and cash flow is real, but at CNY 51.90 the A-share already prices much of that repair while clean earnings quality and governance credibility still need proof, leaving little margin of safety.
44/100
76Buffett
Eckert & Ziegler SE: A Better Business, Not Yet a Better Price
Eckert & Ziegler is a Berlin-based radioisotope specialist supplying generators, isotope products and CDMO services whose Medical segment is becoming the group's real profit engine as radiopharmaceutical oncology increasingly relies on lutetium-177 and actinium-225. 2025 revenue reached €312.0 million with Medical gross margin climbing to 49% and net financial position ending the year at €115.2 million, but 2026 guidance implies only about 3% revenue and adjusted-EBIT growth. Rating Hold: at €14.43 the stock already sits close to its conservative fair-value zone of €11.0–11.8, leaving minimal margin of safety for new buyers.
40/100
53Buffett
Sumitomo Electric Industries: The Transition Is Real, But So Is the Price
Sumitomo Electric is a diversified Japanese cable-and-components maker whose profit mix is shifting away from its low-margin automotive wire-harness base toward higher-margin AI-driven optical interconnects and high-voltage power cables. FY2025 sales reached ¥5.11 trillion with operating profit up 30.4% to ¥418.2 billion, but a meaningful share of the profit surge came from a one-off ¥79.2 billion asset-sale gain, and management's own FY2027 guidance implies only modest further growth. Rating Hold: at ¥2,458.5 the stock already prices much of the transition, leaving no margin of safety at the current level.
46/100
Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act
Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.
33/100
Uranium Energy Corp: Scarce U.S. Uranium Assets, Priced Ahead of the Proof
Uranium Energy Corp is a U.S. in-situ-recovery uranium miner running the country's only two active ISR production hubs, in Wyoming and South Texas, while building toward a domestic conversion business through its UR&C subsidiary. The balance sheet is genuinely strong, with $489.9 million in cash plus restricted cash and no debt as of April 2026, but five-year operating cash flow totaled roughly negative $192.8 million, 2025 revenue of $66.8 million still came mainly from selling purchased inventory rather than mined output, and shares outstanding rose from 378.5 million to 493.3 million since 2023. Rating Avoid: the licensed U.S. permits and policy tailwinds are real, but at $10.07 the stock already sits above even the report's optimistic per-share fair value of $9.02, leaving no margin of safety.
45/100
55Buffett
Vicor: A Real Power-Delivery Specialist, Already Priced For AI's Promise
Vicor is a specialist power-conversion supplier whose Factorized Power Architecture and modular DC-DC building blocks target the 'last-inch' power-delivery bottleneck between AI processors and the board, monetizing both product sales and a fast-growing patent-royalty stream. Full-year 2025 revenue rose 13.5% to $407.7 million with gross margin reaching 57.3% as royalty revenue grew from $15.9 million in 2023 to $57.4 million in 2025, and first-quarter 2026 backlog jumped 75% year over year to $301 million, yet the company still has not disclosed the hyperscaler customers the market assumes it serves. Rating Watch: the technical edge and momentum are real, but at a trailing P/E above 84x and zero margin of safety against the conservative scenario, the stock already prices years of unproven customer breadth.